Genome-wide association study of severe Covid-19 with respiratory failure {#sec1}
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Ellinghaus and Severe Covid-19 GWAS Group (N Engl J Med June 17, 2020;[https://doi.org/10.1056/NEJMoa2020283](10.1056/NEJMoa2020283){#intref0010}, PMID 32558485) used genome-wide association analysis (GWAS) to identify potential genetic factors involved in the development and severity of coronavirus disease 2019 (Covid-19). A total of 1610 patients with Covid-19 and severe disease (defined as respiratory failure) at 7 hospitals in the Italian and Spanish epicenters of the Covid-19 pandemic are included in the study compared with 2205 control participants. Analyses of 8,582,968 single-nucleotide polymorphisms were performed. There were significant cross-replicating associations with rs11385942 at locus 3p21.31 and rs657152 at locus 9q34.2. At locus 3p21.31, the association signal included the genes *SLC6A20*, *LZTFL1*, *CCR9*, *FYCO1*, *CXCR6*, and *XCR1*. The association signal at locus 9q34.2 coincided with the *ABO* blood group locus, with a higher risk in blood group A than in other blood groups and a protective effect in blood group O. *The authors conclude that a 3p21.31 gene cluster represents a genetic susceptibility locus in patients with severe Covid-19 as well as a potential involvement of the ABO blood group system.*
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A vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to control the current pandemic from coronavirus infectious disease (COVID-19). Corbett et al (N Engl J Med July 28, 2020;doi:10.1056/NEJMoa2024671; PMID 32722908) investigated the effect of a messenger RNA (mRNA) vaccine on viral replication in both upper and lower airways in nonhuman primates, receiving 10 or 100 μg of mRNA-1273, a vaccine encoding the prefusion-stabilized spike protein of SARS-CoV-2, currently in phase 3 clinical trial. The authors demonstrated that the mRNA-1273 vaccine candidate induced antibody levels exceeding those in human convalescent-phase serum. Vaccination induced type 1 helper T cell (Th1)--biased CD4 T-cell responses and low or undetectable Th2 or CD8 T-cell responses. Viral replication was not detectable in bronchoalveolar-lavage fluid or in the nose of the animals after challenge in vaccinated groups. *The authors conclude that v* *accination of nonhuman primates with mRNA-1273 induced robust SARS-CoV-2 neutralizing activity, rapid protection in the upper and lower airways, with no pathologic changes in the lung.*

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomized controlled trial {#sec3}
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Folegatti et al (Lancet July 20, 2020;[https://doi.org/10.1016/S0140-6736(2031604-4](10.1016/S0140-6736(2031604-4){#intref0020}), PMID 327022980) investigated the safety, reactogenicity, and immunogenicity of a viral vectored coronavirus vaccine in a phase 1/2, single-blind, randomized controlled trial. Specifically, a chimpanzee adenovirus-vectored vaccine (ChAdOx1 nCoV-19) expressing the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein was compared with a meningococcal conjugate vaccine (MenACWY, Nimenrix, Pfizer, UK) as control vaccine. A total of 1077 participants were enrolled. Local and systemic reactions were more common in the ChAdOx1 nCoV-19 group, but there were no serious adverse events. Additionally, in the ChAdOx1 nCoV-19 group, spike-specific T-cell responses peaked on day 14 with rising anti-spike IgG responses by day 28. Neutralizing antibody responses against SARS-CoV-2 were detected in the majority of the participants and all participants after a booster dose. The authors conclude that *ChAdOx1 nCoV-19 showed an acceptable safety profile and homologous boosting increased antibody responses. The results* *support* *large-scale evaluation of this candidate vaccine in an ongoing phase 3 study.*
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Ribeiro et al (Nat Commun 2020;11:1760, PMID 32273514) evaluated the utility of deep neural networks (DNNs), composed of stacked transformations that learn tasks by examples, in the 12-lead electrocardiogram (ECG). A DNN model was trained in a data set with more than 2 million labeled examinations analyzed by the Telehealth Network and collected under the scope of the CODE (Clinical Outcomes in Digital Electrocardiography) study. The DNN outperforms cardiology medical residents in recognizing 6 types of abnormalities in 12-lead ECG recordings, with F1 scores above 80% and specificity over 99%. *The authors conclude that ECG analysis based on DNNs, previously studied in a single-lead setup, generalizes well to 12-lead examinations and provides a potential use of the technology in the standard clinical practice.*
